Advanced search
Publication Cover
Postgraduate Medicine Volume 121, 2009 - Issue 5
Submit an article Journal homepage
16
Views
4
CrossRef citations to date
0
Altmetric
Clinical Features

Lack of Nephrotoxicity of Gadodiamide in Unselected Hospitalized Patients

Hariprasad Trivedi Medical College of Wisconsin, Milwaukee, WICorrespondence[email protected]
, MD,
Lakshmi Raman Medical College of Wisconsin, Milwaukee, WI
, MD,
Heather Benjamin Medical College of Wisconsin, Milwaukee, WI
, MD &
Ruchika Batwara Medical College of Wisconsin, Milwaukee, WI
, MD
Pages 166-170 | Published online: 13 Mar 2015

References

  • . Swan SK, Lambrecht LJ, Townsend R, . Safety and pharmacokinetic profile of gadobenate dimeglumine in subjects with renal impairment. Invest Radiol. 1999;34(7):443–448
  • . Swan SK, Baker JF, Free R, . Pharmacokinetics, safety, and tolerability of gadoversetamide injection (OptiMARK) in subjects with central nervous system or liver pathology and varying degrees of renal function. J Magn Reson Imaging. 1999;9(2):317–321
  • . Nyman U, Elmståhl B, Leander P, Nilsson M, Golman K, Almén T. Are gadolinium-based contrast media really safer than iodinated media for digital substraction angiography in patients with azotemia? Radiology. 2002;223(2):311–318
  • . Niendorf HP, Haustein J, Cornelius I, Alhassan A, Clauss W. Safety of gadolinium-DTPA: extended clinical experience. Magn Reson Med. 1991;22(2):222–228; discussion 229–232
  • . Ergün I, Keven K, Uruf I, . The safety of gadolinium in patients with stage 3 and 4 renal failure. Nephrol Dial Transplant. 2006;21(3):697–700
  • . Haustein J, Niendorf HP, Krestin G, . Renal tolerance of gadolinium-DTPA/dimeglumine in patients with chronic renal failure. Invest Radiol. 1992;27(2):153–156
  • . Gemmette JJ, Forauer AR, Kazanjian S, Dasika N. Safety of large volume angiography. (Abstract). J Vasc Interv Radiol. 2001;12( suppl 1):S28
  • . Kaufman JA, Geller SC, Waltman AC. Renal insufficiency: gadopentetate dimeglumine as a radiographic contrast agent during peripheral vascular interventional procedures. Radiology. 1996;198(2):579–581
  • . Swaminathan S, Shah SV. New insights into nephrogenic systemic fibrosis. J Am Soc Nephrol. 2007;18(10):2636–2643
  • . Leander P, Allard M, Caille JM, Golman K. Early effect of gadopentate and iodinated contrast media on rabbit kidneys. Invest Radiol. 1992;27(110):922–926
  • . Kelly AM, Dwamena B, Cronin P, Bernstein SJ, Carlos RC. Meta-analysis: effectiveness of drugs for preventing contrast-induced nephropathy. Ann Intern Med. 2008;148(4):284–294
  • . Solomon R, Barrett B. Follow-up of patients with contrast-induced nephropathy. Kidney Int. 2006;69( suppl):S46–S50
  • . Thomsen HS, Dorph S, Larsen S, . Urine profiles and kidney histology after intravenous injection of ionic and nonionic radiologic and magnetic resonance contrast media in normal rats. Acad Radiol. 1994;1(2):128–135
  • . Thomsen HS, Dorph S, Larsen S, . Urine profiles and kidney histology after ionic and nonionic radiologic and magnetic resonance contrast media in rats with cisplatin nephropathy. Acad Radiol. 1995;2(8):675–682
  • . Brillet G, Dubois M, Beaufils H, Bourbouze R, Deray G. Renal tolerance of gadolinium-DOTA and gadolinium-DTPA in rats. Invest Radiol. 1994;29(3):352–354
  • . Haustein J, Niendorf HP, and Louton T. Renal tolerance of Gd-DTPA in 1,171 patients. Abstract. Radiology. 1990;177(P):167
  • . Niendorf HP, Haustein J, Louton T, Beck W, and Laniado M. Safety and tolerance after intravenous administration of 0.3 mmol/kg Gd-DTPA. Results of a randomized, controlled trial. Invest Radiol. 1991;26( suppl 1):S221–S223
  • . Solomon R. Contrast-medium-induced acute renal failure. Kidney Int. 1998;53(1):230–242
  • . Sam AD II, Morasch MD, Collins J, Song G, Chen R, Pereles FS. Safety of gadolinium contrast angiography in patients with chronic renal insufficiency. J Vasc Surg. 2003;38(2):313–318

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.